These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 24419412

  • 1. Biomarkers and receptor targeted therapies reduce clinical trial risk in non-small-cell lung cancer.
    Falconi A, Lopes G, Parker JL.
    J Thorac Oncol; 2014 Feb; 9(2):163-9. PubMed ID: 24419412
    [Abstract] [Full Text] [Related]

  • 2. U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive.
    Malik SM, Maher VE, Bijwaard KE, Becker RL, Zhang L, Tang SW, Song P, Liu Q, Marathe A, Gehrke B, Helms W, Hanner D, Justice R, Pazdur R.
    Clin Cancer Res; 2014 Apr 15; 20(8):2029-34. PubMed ID: 24573551
    [Abstract] [Full Text] [Related]

  • 3. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.
    Scagliotti G, Stahel RA, Rosell R, Thatcher N, Soria JC.
    Eur J Cancer; 2012 May 15; 48(7):961-73. PubMed ID: 22397764
    [Abstract] [Full Text] [Related]

  • 4. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
    O'Bryant CL, Wenger SD, Kim M, Thompson LA.
    Ann Pharmacother; 2013 Feb 15; 47(2):189-97. PubMed ID: 23386065
    [Abstract] [Full Text] [Related]

  • 5. Impact of biomarkers on clinical trial risk in breast cancer.
    Parker JL, Lushina N, Bal PS, Petrella T, Dent R, Lopes G.
    Breast Cancer Res Treat; 2012 Nov 15; 136(1):179-85. PubMed ID: 23007573
    [Abstract] [Full Text] [Related]

  • 6. Clinical trial risk in leukemia: Biomarkers and trial design.
    Li AJ, Dhanraj JP, Lopes G, Parker JL.
    Hematol Oncol; 2021 Feb 15; 39(1):105-113. PubMed ID: 33078436
    [Abstract] [Full Text] [Related]

  • 7. Looking for a new panacea in ALK-rearranged NSCLC: may be Ceritinib?
    Rolfo C, Passiglia F, Russo A, Pauwels P.
    Expert Opin Ther Targets; 2014 Sep 15; 18(9):983-5. PubMed ID: 24998601
    [Abstract] [Full Text] [Related]

  • 8. Review of ongoing clinical trials in non-small-cell lung cancer: a status report for 2012 from the ClinicalTrials.gov Web site.
    Subramanian J, Regenbogen T, Nagaraj G, Lane A, Devarakonda S, Zhou G, Govindan R.
    J Thorac Oncol; 2013 Jul 15; 8(7):860-5. PubMed ID: 23478543
    [Abstract] [Full Text] [Related]

  • 9. Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.
    Roengvoraphoj M, Tsongalis GJ, Dragnev KH, Rigas JR.
    Cancer Treat Rev; 2013 Dec 15; 39(8):839-50. PubMed ID: 23768755
    [Abstract] [Full Text] [Related]

  • 10. Targeted therapies for non-small cell lung cancer.
    Dempke WC, Suto T, Reck M.
    Lung Cancer; 2010 Mar 15; 67(3):257-74. PubMed ID: 19914732
    [Abstract] [Full Text] [Related]

  • 11. Current FDA-approved treatments for non-small cell lung cancer and potential biomarkers for its detection.
    Ruiz-Ceja KA, Chirino YI.
    Biomed Pharmacother; 2017 Jun 15; 90():24-37. PubMed ID: 28340378
    [Abstract] [Full Text] [Related]

  • 12. Targeting fibroblast growth factor receptor and discoidin domain receptor 2 in non-small-cell lung cancer.
    Riess JW, Neal JW.
    J Thorac Oncol; 2012 Dec 15; 7(16 Suppl 5):S385-6. PubMed ID: 23160327
    [No Abstract] [Full Text] [Related]

  • 13. Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists.
    Silvestri GA, Rivera MP.
    Chest; 2005 Dec 15; 128(6):3975-84. PubMed ID: 16354869
    [Abstract] [Full Text] [Related]

  • 14. Onartuzumab in lung cancer: the fall of Icarus?
    Rolfo C, Van Der Steen N, Pauwels P, Cappuzzo F.
    Expert Rev Anticancer Ther; 2015 May 15; 15(5):487-9. PubMed ID: 25818471
    [Abstract] [Full Text] [Related]

  • 15. Molecularly targeted therapies in locally advanced non-small-cell lung cancer.
    Devarakonda S, Morgensztern D, Govindan R.
    Clin Lung Cancer; 2013 Sep 15; 14(5):467-72. PubMed ID: 23684057
    [Abstract] [Full Text] [Related]

  • 16. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
    Rodig SJ, Shapiro GI.
    Curr Opin Investig Drugs; 2010 Dec 15; 11(12):1477-90. PubMed ID: 21154129
    [Abstract] [Full Text] [Related]

  • 17. Recent advances in squamous non-small cell lung cancer: evidence beyond predictive biomarkers.
    Genova C, Rijavec E, Grossi F.
    Expert Rev Anticancer Ther; 2016 Dec 15; 16(1):1-4. PubMed ID: 26567561
    [Abstract] [Full Text] [Related]

  • 18. Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis.
    Parker JL, Kuzulugil SS, Pereverzev K, Mac S, Lopes G, Shah Z, Weerasinghe A, Rubinger D, Falconi A, Bener A, Caglayan B, Tangri R, Mitsakakis N.
    Cancer Med; 2021 Mar 15; 10(6):1955-1963. PubMed ID: 33620160
    [Abstract] [Full Text] [Related]

  • 19. Advances towards the design and development of personalized non-small-cell lung cancer drug therapy.
    Vari S, Pilotto S, Maugeri-Saccà M, Ciuffreda L, Cesta Incani U, Falcone I, Del Curatolo A, Ceribelli A, Gelibter A, De Maria R, Tortora G, Cognetti F, Bria E, Milella M.
    Expert Opin Drug Discov; 2013 Nov 15; 8(11):1381-97. PubMed ID: 24088065
    [Abstract] [Full Text] [Related]

  • 20. Consensus report of a joint NCI thoracic malignancies steering committee: FDA workshop on strategies for integrating biomarkers into clinical development of new therapies for lung cancer leading to the inception of "master protocols" in lung cancer.
    Malik SM, Pazdur R, Abrams JS, Socinski MA, Sause WT, Harpole DH, Welch JJ, Korn EL, Ullmann CD, Hirsch FR.
    J Thorac Oncol; 2014 Oct 15; 9(10):1443-8. PubMed ID: 25521397
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.